NASDAQ : MLTX
MoonLake Immunotherapeutics — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 11.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.00B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 976.17M |
| Enterprise Value | 540.68M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 85.11M |
| Shares Outstanding | 85.11M |
| Shares Change (YoY) | +9.53% |
| Shares Change (QoQ) | +3.71% |
| Owned by Insiders (%) | 7.80% |
| Owned by Institutions (%) | 60.39% |
| Float | 55.47M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 3,711.69 |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.56 |
| Quick Ratio | 11.98 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.59 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -67.47% |
| Return on Assets (ROA) | -32.44% |
| Return on Invested Capital (ROIC) | -34.81% |
| Return on Capital Employed (ROCE) | -50.77% |
| Weighted Average Cost of Capital (WACC) | 9.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.03M |
| Employee Count | 130 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.08M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +13.56% |
| 50-Day Moving Average | 12.44 |
| 200-Day Moving Average | 16.44 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 1,962,240 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.83M |
| Short Previous Month | 8.05M |
| Short % of Shares Out | 9.20% |
| Short % of Float | 14.12% |
| Short Ratio (days to cover) | 4.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -268.34M |
| Pretax Income | -264.15M |
| Net Income | -263.67M |
| EBITDA | -265.10M |
| EBIT | -268.34M |
| Earnings Per Share (EPS) | -$3.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 537.03M |
| Total Debt | 101.53M |
| Net Cash | 435.50M |
| Net Cash Per Share | $5.12 |
| Equity (Book Value) | 428.20M |
| Book Value Per Share | 5.12 |
| Working Capital | 524.65M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -225.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.24M |
| Net Borrowing | 24.47M |
| Free Cash Flow | -225.18M |
| FCF Per Share | -$2.65 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.53% |
| Shareholder Yield | -9.53% |
| Earnings Yield | -33.25% |
| FCF Yield | -23.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $28.54 |
| Price Target Difference | 148.82% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |